Alpha cell function in health and disease: influence of glucagon-like peptide-1

[1]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. , 2004, Diabetes care.

[2]  O. Schmitz,et al.  GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. , 2004, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[3]  Dennis D. Kim,et al.  Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. , 2004, Diabetes.

[4]  C. Deacon.  Therapeutic strategies based on glucagon-like peptide 1. , 2004, Diabetes.

[5]  J. Holst,et al.  Additive effects of glucagon-like peptide 1 and pioglitazone in patients with type 2 diabetes. , 2004, Diabetes care.

[6]  A. Astrup,et al.  The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. , 2004, Diabetes care.

[7]  J. Ranstam,et al.  Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. , 2004, Diabetes care.

[8]  Bo Ahrén,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels , 2022 .

[9]  Jeppe Sturis,et al.  One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. , 2004, Diabetes.

[10]  J. Holst,et al.  Incretins, insulin secretion and Type 2 diabetes mellitus , 2004, Diabetologia.

[11]  Andrea Mari,et al.  Characterization of GLP-1 effects on beta-cell function after meal ingestion in humans. , 2003, Diabetes care.

[12]  N. Greig,et al.  Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. , 2003, Diabetes care.

[13]  Dennis D. Kim,et al.  Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. , 2003, Diabetes care.

[14]  J. Holst,et al.  Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects , 2003, Regulatory Peptides.

[15]  Dennis D. Kim,et al.  Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[16]  A. Chang,et al.  The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose. , 2003, Diabetes.

[17]  P. Cryer,et al.  Hypoglycemia in diabetes. , 2003, Diabetes care.

[18]  J. Holst,et al.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[19]  J. Holst,et al.  Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia , 2003, Diabetologia.

[20]  R. Silvestre,et al.  Interrelationship among insulin, glucagon and somatostatin secretory responses to exendin-4 in the perfused rat pancreas. , 2003, European journal of pharmacology.

[21]  D. D’Alessio,et al.  Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. , 2003, The Journal of clinical endocrinology and metabolism.

[22]  J. Sturis,et al.  NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs. , 2002, European journal of pharmacology.

[23]  R. Pederson,et al.  Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study. , 2002, Diabetes.

[24]  J. Holst,et al.  Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients , 2002, Diabetologia.

[25]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[26]  J. Holst,et al.  Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. , 2002, The Journal of clinical endocrinology and metabolism.

[27]  T. Hughes,et al.  Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. , 2002, The Journal of endocrinology.

[28]  J. Sturis,et al.  Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. , 2002, Diabetes.

[29]  B. Ahrén,et al.  Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations , 2001, Diabetologia.

[30]  J. Holst,et al.  Antidiabetogenic action of glucagon‐like peptide‐1 related to administration relative to meal intake in subjects with type 2 diabetes , 2001, Journal of internal medicine.

[31]  A. Astrup,et al.  The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity , 2001, International Journal of Obesity.

[32]  J. Holst,et al.  Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. , 2001, Diabetes care.

[33]  B. Ahrén,et al.  Differential Effects of Glucagon-like Peptide-1 (7-36)Amide Versus Cholecystokinin on Arginine-Induced Islet Hormone Release In Vivo and In Vitro , 2001, Pancreas.

[34]  E. Ferrannini,et al.  Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study. , 2000, Diabetes.

[35]  B. Ahrén,et al.  Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. , 2000, Diabetes care.

[36]  A. Astrup,et al.  The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans , 2000, International Journal of Obesity.

[37]  B. Ahrén,et al.  Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study in postmenopausal Caucasian women , 2000, Diabetologia.

[38]  J. Habener,et al.  The glucagon-like peptides. , 1999, Endocrine reviews.

[39]  J. Holst,et al.  Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. , 1998, Diabetes care.

[40]  B. Ahrén,et al.  Autonomic mediation of glucagon secretion during hypoglycemia: implications for impaired alpha-cell responses in type 1 diabetes. , 1998, Diabetes.

[41]  A. Ryan,et al.  Insulinotropic hormone glucagon-like peptide-1-(7-37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. , 1998, The Journal of clinical endocrinology and metabolism.

[42]  B. Göke,et al.  Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans. , 1998, The Journal of clinical investigation.

[43]  J. Holst,et al.  GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions , 1997, Diabetes Care.

[44]  J. Holst,et al.  Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. , 1997, American journal of physiology. Endocrinology and metabolism.

[45]  J. Holst,et al.  Pituitary adenylate cyclase-activating polypeptide stimulates insulin and glucagon secretion in humans. , 1997, The Journal of clinical endocrinology and metabolism.

[46]  S. Dinneen,et al.  The Postprandial State: Mechanisms of Glucose Intolerance , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[47]  S. Bloom,et al.  Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus , 1997, European journal of clinical investigation.

[48]  B. Ahrén,et al.  Activation of Autonomic Nerves and the Adrenal Medulla Contributes to Increased Glucagon Secretion During Moderate Insulin-Induced Hypoglycemia in Women , 1997, Diabetes.

[49]  P. Rorsman,et al.  Glucagon-Like Peptide I and Glucose-Dependent Insulinotropic Polypeptide Stimulate Ca2+-Induced Secretion in Rat α-Cells by a Protein Kinase A–Mediated Mechanism , 1997, Diabetes.

[50]  J. Holst,et al.  Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus. , 1997, The Journal of clinical endocrinology and metabolism.

[51]  S A BERSON,et al.  Immunoassay of endogenous plasma insulin in man. , 1996, The Journal of clinical investigation.

[52]  J. Holst,et al.  Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patients , 1996, Diabetes Care.

[53]  J. Holst,et al.  Effects of glucagon-like peptide-I on glucose turnover in rats. , 1996, The American journal of physiology.

[54]  D. Pipeleers,et al.  Expression and Functional Activity of Glucagon, Glucagon-Like Peptide I, and Glucose-Dependent Insulinotropic Peptide Receptors in Rat Pancreatic Islet Cells , 1996, Diabetes.

[55]  R. Heller,et al.  Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide. , 1995, The American journal of physiology.

[56]  R. Bretzel,et al.  The Effects of Glucagon‐like Peptide‐I (GLP‐I) on Hormone Secretion from Isolated Human Pancreatic Islets , 1995, Pancreas.

[57]  J. Holst,et al.  Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7–36 amide] after subcutaneous injection in healthy volunteers. Dose-response-relationships , 1995, Diabetologia.

[58]  J. Holst,et al.  Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM , 1994, Diabetes Care.

[59]  S. Parry,et al.  Redundant parasympathetic and sympathoadrenal mediation of increased glucagon secretion during insulin-induced hypoglycemia in conscious rats. , 1994, Metabolism: clinical and experimental.

[60]  J. Holst,et al.  Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[61]  J. Holst,et al.  Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man , 1993, Digestive Diseases and Sciences.

[62]  Y. Matsuzawa,et al.  Glucagonlike peptide-1(7-36)amide suppresses glucagon secretion and decreases cyclic AMP concentration in cultured In-R1-G9 cells. , 1992, Biochemical and biophysical research communications.

[63]  J. Holst,et al.  Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. , 1992, The New England journal of medicine.

[64]  D. Kelley,et al.  Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. , 1992, The New England journal of medicine.

[65]  E. Samols,et al.  The Vascular Order of Islet Cellular Perfusion in the Human Pancreas , 1992, Diabetes.

[66]  M. Shichiri,et al.  Abnormal glucagon response to arginine and its normalization in obese hyperinsulinaemic patients with glucose intolerance: importance of insulin action on pancreatic Alpha cells , 1991, Diabetologia.

[67]  S. Ohashi,et al.  The structure-function relationship of GLP-1 related peptides in the endocrine function of the canine pancreas. , 1991, The Tohoku journal of experimental medicine.

[68]  C. Greenbaum,et al.  Intra-islet insulin permits glucose to directly suppress pancreatic A cell function. , 1991, The Journal of clinical investigation.

[69]  F. Sundler,et al.  GLP‐1 and GLP‐17‐36 Amide: Influences on Basal and Stimulated Insulin and Glucagon Secretion in the Mouse , 1991, Pancreas.

[70]  G. Paolisso,et al.  Effects of oxytocin upon the endocrine pancreas secretion and glucose turnover in normal man. , 1990, Acta endocrinologica.

[71]  T. Ogihara,et al.  Suppression of synthesis and release of glucagon by glucagon-like peptide-1 (7-36 amide) without affect on mRNA level in isolated rat islets. , 1990, Biochemical and biophysical research communications.

[72]  S. Ohashi,et al.  Comparison of the effects of various C-terminal and N-terminal fragment peptides of glucagon-like peptide-1 on insulin and glucagon release from the isolated perfused rat pancreas. , 1989, Endocrinology.

[73]  J. Palmer,et al.  Responses of the pancreatic A cell during hypoglycemia and hyperglycemia are dependent on the B cell. , 1989, Metabolism: clinical and experimental.

[74]  M. Namba,et al.  Glucagonostatic and Insulinotropic Action of Glucagonlike Peptide I-(7–36)-Amide , 1989, Diabetes.

[75]  K. Alberti,et al.  METABOLIC AND HORMONAL RESPONSES TO EXOGENOUS HYPERTHERMIA IN MAN , 1989, Clinical endocrinology.

[76]  S. Ohashi,et al.  Comparison of the effects of glucagon-like peptide-1-(1-37) and -(7-37) and glucagon on islet hormone release from isolated perfused canine and rat pancreases. , 1989, Endocrinology.

[77]  M. Namba,et al.  Glucagon-like peptide-1 (7-36 amide): a potent glucagonostatic and insulinotropic hormone. , 1988, Diabetes research and clinical practice.

[78]  J. Holst,et al.  Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. , 1988, Endocrinology.

[79]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[80]  I. Macdonald,et al.  Counterregulation in Type 2 (non-insulin-dependent) diabetes mellitus. Normal endocrine and glycaemic responses, up to ten years after diagnosis , 1987, Diabetologia.

[81]  I. Goldfine,et al.  Physiological concentrations of cholecystokinin stimulate amino acid-induced insulin release in humans. , 1987, The Journal of clinical endocrinology and metabolism.

[82]  Yasuo Ito,et al.  Effect of β-hydroxybutyrate and acetoacetate on insulin and glucagon secretion from perfused rat pancreas , 1987 .

[83]  B. Ahrén,et al.  Sympathetic nerve stimulation versus pancreatic norepinephrine infusion in the dog: 1). Effects on basal release of insulin and glucagon. , 1987, Endocrinology.

[84]  J. Halter,et al.  Relationship of islet function to insulin action in human obesity. , 1987, The Journal of clinical endocrinology and metabolism.

[85]  T. Hökfelt,et al.  Occurrence of VIP and peptide HM in human pancreas and their influence on pancreatic endocrine secretion in man , 1987, Regulatory Peptides.

[86]  A. Baron,et al.  Role of Hyperglucagonemia in Maintenance of Increased Rates of Hepatic Glucose Output in Type II Diabetics , 1987, Diabetes.

[87]  G. Weir,et al.  Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. , 1987, The Journal of clinical investigation.

[88]  B. Ahrén,et al.  The mechanism of vagal nerve stimulation of glucagon and insulin secretion in the dog. , 1986, Endocrinology.

[89]  J. Halter,et al.  Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. , 1984, The Journal of clinical investigation.

[90]  J. Holst,et al.  Gastrin-releasing peptide: pharmacokinetics and effects on gastro-entero-pancreatic hormones and gastric secretion in normal men. , 1984, The Journal of clinical endocrinology and metabolism.

[91]  P. Cryer,et al.  Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine intera , 1984, The Journal of clinical investigation.

[92]  G. Taborsky.  Evidence of a paracrine role for pancreatic somatostatin in vivo. , 1983, The American journal of physiology.

[93]  J. Palmer,et al.  Glucose Modulation of Insulin and Glucagon Secretion in Nondiabetic and Diabetic Man , 1982, Diabetes.

[94]  B. Ahrén,et al.  Glucagon immunoreactivity in plasma from normal and dystrophic mice , 1982, Diabetologia.

[95]  R. DeFronzo,et al.  Sensitivity of insulin secretion to feedback inhibition by hyperinsulinaemia. , 1981, Acta endocrinologica.

[96]  D. Porte,et al.  Hyperglucagonemia and alpha-adrenergic receptor in acute hypoxia. , 1979, The American journal of physiology.

[97]  J. Halter,et al.  Differential effect of isoproterenol on acute glucagon and insulin release in man. , 1979, Metabolism: clinical and experimental.

[98]  S. Oikawa,et al.  Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus. , 1978, The Journal of clinical endocrinology and metabolism.

[99]  P. Bennett,et al.  Immunoreactive glucagon (IRG) responses to intravenous glucose in prediabetes and diabetes among Pima Indians and normal Caucasians. , 1977, The Journal of clinical endocrinology and metabolism.

[100]  M. Lorenzi,et al.  Comparison of the suppressive effects of elevated plasma glucose and free fatty acid levels on glucagon secretion in normal and insulin-dependent diabetic subjects. Evidence for selective alpha-cell insensitivity to glucose in diabetes mellitus. , 1976, The Journal of clinical investigation.

[101]  E. Tsalikian,et al.  Normalization of fasting hyperglucagonemia and excessive glucagon responses to intravenous arginine in human diabetes mellitus by prolonged infusion of insulin. , 1975, The Journal of clinical endocrinology and metabolism.

[102]  S. Yen,et al.  The inhibitory effect of somatostatin on growth hormone, insulin and glucagon secretion in diabetes mellitus. , 1975, The Journal of clinical endocrinology and metabolism.

[103]  E. Tsalikian,et al.  Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon. , 1975, The New England journal of medicine.

[104]  C. J. Goodner,et al.  Somatostatin blockade of acute and chronic stimuli of the endocrine pancreas and the consequences of this blockade on glucose homeostasis. , 1975, The Journal of clinical investigation.

[105]  L. Orci,et al.  THE ESSENTIAL ROLE OF GLUCAGON IN THE PATHOGENESIS OF DIABETES MELLITUS , 1975, The Lancet.

[106]  G. Grodsky,et al.  Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas. , 1974, The Journal of clinical investigation.

[107]  J. Gerich,et al.  Lack of Glucagon Response to Hypoglycemia in Diabetes: Evidence for an Intrinsic Pancreatic Alpha Cell Defect , 1973, Science.

[108]  J. Gerich,et al.  Stimulation of glucagon secretion by epinephrine in man. , 1973, The Journal of clinical endocrinology and metabolism.

[109]  D. M. Rocha,et al.  Glucagon-stimulating activity of 20 amino acids in dogs. , 1972, The Journal of clinical investigation.

[110]  R. Unger,et al.  Suppressive effect of secretin upon pancreatic alpha cell function. , 1972, The Journal of clinical investigation.

[111]  W. A. Müller,et al.  Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. , 1970, The New England journal of medicine.

[112]  W. A. Müller,et al.  Studies of pancreatic alpha cell function in normal and diabetic subjects. , 1970, The Journal of clinical investigation.

[113]  R. Unger,et al.  Glucagon antibodies and an immunoassay for glucagon. , 1961, The Journal of clinical investigation.

[114]  T. McDonald,et al.  Glucagon-like peptide 1 improved glycemic control in type 1 diabetes , 2003, BMC endocrine disorders.

[115]  J. Sturis,et al.  Bedtime Administration of NN 2211 , a Long-Acting GLP-1 Derivative , Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes , 2002 .

[116]  J. Holst,et al.  Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. , 1996, The Journal of clinical endocrinology and metabolism.

[117]  D. D’Alessio,et al.  Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. , 1996, The Journal of clinical investigation.

[118]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[119]  I Kiss,et al.  Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. , 1991, The American journal of physiology.

[120]  M Ljungström,et al.  Calcium oscillations and morphological transformations in single cultured gastric parietal cells. , 1991, The American journal of physiology.

[121]  R. Hartung.  Dose—Response Relationships , 1987 .

[122]  B. Dunning,et al.  Actions of neurohypophysial peptides on pancreatic hormone release. , 1984, The American journal of physiology.

[123]  Graeme I. Bell,et al.  Exon duplication and divergence in the human preproglucagon gene , 1983, Nature.

[124]  G WhittakerP,et al.  共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値 , 1980 .

[125]  B. Jaffe,et al.  Methods of Hormone Radioimmunoassay , 1974 .